Hypertension and COVID-19: Potential use of beta-blockers and a call for Randomized Evidence
Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in CO...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article PeerReviewed |
| Language: | English English English English |
| Published: |
Cardiological Society of India
2021
|
| Subjects: | |
| Online Access: | https://repository.unair.ac.id/125540/1/1.%20Hypertension%20and%20COVID-19%20Potential%20use%20of%20beta-blockers%20and%20a%20call%20for%20evidenc_IHJ%202021.pdf https://repository.unair.ac.id/125540/2/karil%201.pdf https://repository.unair.ac.id/125540/3/1.%20Korespondensi.pdf https://repository.unair.ac.id/125540/4/1.%20Turnitin.pdf https://repository.unair.ac.id/125540/ https://www.sciencedirect.com/science/article/pii/S0019483221002303?via%3Dihub https://doi.org/10.1016/j.ihj.2021.10.011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Universitas Airlangga |
| Language: | English English English English |
| Summary: | Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in COVID-19 treatment, with current evidence of the potential mechanism of beta-blockers remains scarce. However, several mechanisms were suggested, including decreasing RAAS pathway activity and lowering the ACE2 levels, reducing cytokine storms, and may be beneficial in reducing mortality in ARDS related COVID-19. Further large-scale randomized clinical trials should be conducted before a definite recommendation can be drawn. |
|---|